Lin Jing, Yu He, Han-Ying Fan, Su-Zhen Wang, Mei Xin, Liu-Zhi Zeng
{"title":"Gonioscopy-assisted transluminal trabeculotomy in the management of uncontrolled Posner-Schlossman syndrome: a retrospective study.","authors":"Lin Jing, Yu He, Han-Ying Fan, Su-Zhen Wang, Mei Xin, Liu-Zhi Zeng","doi":"10.18240/ijo.2026.10.23","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To explore the efficacy and safety of gonioscopy-assisted transluminal trabeculotomy (GATT) in the treatment of Posner-Schlossman syndrome (PSS).</p><p><strong>Methods: </strong>A retrospective review was conducted on participants diagnosed with PSS and uncontrolled intraocular pressure (IOP) who underwent GATT between 2023 and 2024. Clinical outcome measures including visual acuity, IOP, gonioscopic findings, complications, and relapses were collected for postoperative visits: 1d, 1wk, 1, 3, 6mo and 1y.</p><p><strong>Results: </strong>Eleven participants (mean age 43.00±13.82y, 5 females and 6 males) were enrolled. Nine participants were followed up for 12mo after the surgery, 1 participant underwent trabeculectomy to decrease the uncontrolled IOP, another participant was followed up for 6mo because of loss of follow-up. The mean IOP before GATT was 33.64±6.21 mm Hg (range: 23-46 mm Hg). The mean number of antiglaucoma medications prior to surgery was 2.73±0.66. At 6mo after the surgery, the mean IOP decreased to 17.36±6.17 mm Hg (47.15%±17.35% reduction). Nine participants were followed up for 12mo, and their mean IOP decreased to 16.22±2.49 mm Hg, with an average IOP reduction of 46.83%±16.93% (<i>P</i><0.01). The number of anti-glaucoma medications significantly decreased to 0.91±0.83 at the last follow-up (<i>P</i><0.05). Two eyes were considered treatment failures due to reintervention and uncontrolled IOP. The preoperative IOP of qualified success cases were significantly lower than that of failed cases. The most common complications were intraoperative anterior chamber blood reflux (100%) and IOP spikes (45.45%), both of which resolved within 1wk. During the follow-up period, 7 participants experienced recurrent attacks of PSS. Nevertheless, peak IOP during relapse was significantly reduced compared to preoperative values (<i>P</i><0.05).</p><p><strong>Conclusion: </strong>GATT seems to be a reliable and effective method for the management of PSS with uncontrolled IOP. Higher preoperative IOP maybe the factor of surgical failure. Although it may not prevent relapse of PSS, it might potentially reduce the peak IOP. Longer-term follow-up and a larger sample size are recommended for more in-depth analysis.</p>","PeriodicalId":14312,"journal":{"name":"International journal of ophthalmology","volume":"19 10","pages":"2076-2082"},"PeriodicalIF":2.0000,"publicationDate":"2026-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13586936/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18240/ijo.2026.10.23","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: To explore the efficacy and safety of gonioscopy-assisted transluminal trabeculotomy (GATT) in the treatment of Posner-Schlossman syndrome (PSS).
Methods: A retrospective review was conducted on participants diagnosed with PSS and uncontrolled intraocular pressure (IOP) who underwent GATT between 2023 and 2024. Clinical outcome measures including visual acuity, IOP, gonioscopic findings, complications, and relapses were collected for postoperative visits: 1d, 1wk, 1, 3, 6mo and 1y.
Results: Eleven participants (mean age 43.00±13.82y, 5 females and 6 males) were enrolled. Nine participants were followed up for 12mo after the surgery, 1 participant underwent trabeculectomy to decrease the uncontrolled IOP, another participant was followed up for 6mo because of loss of follow-up. The mean IOP before GATT was 33.64±6.21 mm Hg (range: 23-46 mm Hg). The mean number of antiglaucoma medications prior to surgery was 2.73±0.66. At 6mo after the surgery, the mean IOP decreased to 17.36±6.17 mm Hg (47.15%±17.35% reduction). Nine participants were followed up for 12mo, and their mean IOP decreased to 16.22±2.49 mm Hg, with an average IOP reduction of 46.83%±16.93% (P<0.01). The number of anti-glaucoma medications significantly decreased to 0.91±0.83 at the last follow-up (P<0.05). Two eyes were considered treatment failures due to reintervention and uncontrolled IOP. The preoperative IOP of qualified success cases were significantly lower than that of failed cases. The most common complications were intraoperative anterior chamber blood reflux (100%) and IOP spikes (45.45%), both of which resolved within 1wk. During the follow-up period, 7 participants experienced recurrent attacks of PSS. Nevertheless, peak IOP during relapse was significantly reduced compared to preoperative values (P<0.05).
Conclusion: GATT seems to be a reliable and effective method for the management of PSS with uncontrolled IOP. Higher preoperative IOP maybe the factor of surgical failure. Although it may not prevent relapse of PSS, it might potentially reduce the peak IOP. Longer-term follow-up and a larger sample size are recommended for more in-depth analysis.
目的:探讨经腔镜辅助的小梁切开术(GATT)治疗Posner-Schlossman综合征(PSS)的疗效和安全性。方法:回顾性分析2023年至2024年期间诊断为PSS和眼压不控制(IOP)的GATT患者。收集术后随访的临床结果指标,包括视力、IOP、角膜炎检查结果、并发症和复发情况:1天、1周、1、3、6个月和1个月。结果:共入组11例,平均年龄43.00±13.82岁,其中女5例,男6例。9名参与者术后随访12个月,1名参与者接受小梁切除术以降低不受控制的IOP,另一名参与者因失去随访而随访6个月。GATT前平均眼压为33.64±6.21 mm Hg(范围:23 ~ 46 mm Hg)。术前抗青光眼药物平均使用次数为2.73±0.66次。术后6个月,平均IOP降至17.36±6.17 mm Hg(47.15%±17.35%)。9例患者随访12个月,平均IOP下降至16.22±2.49 mm Hg,平均IOP下降46.83%±16.93% (ppp)结论:GATT治疗PSS伴IOP失控是一种可靠有效的方法。术前IOP偏高可能是手术失败的因素。虽然它可能不能防止PSS复发,但它可能潜在地降低IOP峰值。建议进行更长期的随访和更大的样本量,以便进行更深入的分析。
期刊介绍:
· International Journal of Ophthalmology-IJO (English edition) is a global ophthalmological scientific publication
and a peer-reviewed open access periodical (ISSN 2222-3959 print, ISSN 2227-4898 online).
This journal is sponsored by Chinese Medical Association Xi’an Branch and obtains guidance and support from
WHO and ICO (International Council of Ophthalmology). It has been indexed in SCIE, PubMed,
PubMed-Central, Chemical Abstracts, Scopus, EMBASE , and DOAJ. IJO JCR IF in 2017 is 1.166.
IJO was established in 2008, with editorial office in Xi’an, China. It is a monthly publication. General Scientific
Advisors include Prof. Hugh Taylor (President of ICO); Prof.Bruce Spivey (Immediate Past President of ICO);
Prof.Mark Tso (Ex-Vice President of ICO) and Prof.Daiming Fan (Academician and Vice President,
Chinese Academy of Engineering.
International Scientific Advisors include Prof. Serge Resnikoff (WHO Senior Speciatist for Prevention of
blindness), Prof. Chi-Chao Chan (National Eye Institute, USA) and Prof. Richard L Abbott (Ex-President of
AAO/PAAO) et al.
Honorary Editors-in-Chief: Prof. Li-Xin Xie(Academician of Chinese Academy of
Engineering/Honorary President of Chinese Ophthalmological Society); Prof. Dennis Lam (President of APAO) and
Prof. Xiao-Xin Li (Ex-President of Chinese Ophthalmological Society).
Chief Editor: Prof. Xiu-Wen Hu (President of IJO Press).
Editors-in-Chief: Prof. Yan-Nian Hui (Ex-Director, Eye Institute of Chinese PLA) and
Prof. George Chiou (Founding chief editor of Journal of Ocular Pharmacology & Therapeutics).
Associate Editors-in-Chief include:
Prof. Ning-Li Wang (President Elect of APAO);
Prof. Ke Yao (President of Chinese Ophthalmological Society) ;
Prof.William Smiddy (Bascom Palmer Eye instituteUSA) ;
Prof.Joel Schuman (President of Association of University Professors of Ophthalmology,USA);
Prof.Yizhi Liu (Vice President of Chinese Ophtlalmology Society);
Prof.Yu-Sheng Wang (Director of Eye Institute of Chinese PLA);
Prof.Ling-Yun Cheng (Director of Ocular Pharmacology, Shiley Eye Center, USA).
IJO accepts contributions in English from all over the world. It includes mainly original articles and review articles,
both basic and clinical papers.
Instruction is Welcome Contribution is Welcome Citation is Welcome
Cooperation organization
International Council of Ophthalmology(ICO), PubMed, PMC, American Academy of Ophthalmology, Asia-Pacific, Thomson Reuters, The Charlesworth Group, Crossref,Scopus,Publons, DOAJ etc.